161 related articles for article (PubMed ID: 16552792)
1. How can 'Hy's law' help the clinician?
Senior JR
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):235-9. PubMed ID: 16552792
[No Abstract] [Full Text] [Related]
2. Hy's law: predicting serious hepatotoxicity.
Temple R
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):241-3. PubMed ID: 16552790
[No Abstract] [Full Text] [Related]
3. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.
Lewis JH
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):221-9. PubMed ID: 16444771
[No Abstract] [Full Text] [Related]
4. Rules and laws of drug hepatotoxicity.
Kaplowitz N
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):231-3. PubMed ID: 16552791
[No Abstract] [Full Text] [Related]
5. Drug-induced hepatotoxicity.
Lee WM
N Engl J Med; 2003 Jul; 349(5):474-85. PubMed ID: 12890847
[No Abstract] [Full Text] [Related]
6. Avoiding hepatic injury from drugs.
Kaplowitz N
Gastroenterology; 1999 Oct; 117(4):759. PubMed ID: 10500055
[No Abstract] [Full Text] [Related]
7. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.
Goldkind L; Laine L
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):213-20. PubMed ID: 16456879
[TBL] [Abstract][Full Text] [Related]
8. Serious liver injury. Leading reason for drug removals, restrictions.
Meadows M
FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559
[No Abstract] [Full Text] [Related]
9. Ximelagatran: an eulogy.
Boos CJ; Lip GY
Thromb Res; 2006; 118(3):301-4. PubMed ID: 16626788
[No Abstract] [Full Text] [Related]
10. Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran.
Southworth H
Stat Med; 2014 Jul; 33(17):2914-23. PubMed ID: 24623062
[TBL] [Abstract][Full Text] [Related]
11. Ximelagatran data fail to impress FDA.
Thompson CA
Am J Health Syst Pharm; 2004 Dec; 61(23):2472, 2474-5, 2480. PubMed ID: 15595219
[No Abstract] [Full Text] [Related]
12. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation.
Hunter EB; Johnston PE; Tanner G; Pinson CW; Awad JA
Am J Gastroenterol; 1999 Aug; 94(8):2299-301. PubMed ID: 10445569
[TBL] [Abstract][Full Text] [Related]
13. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.
Boudes PF
Contemp Clin Trials; 2006 Oct; 27(5):432-40. PubMed ID: 16769255
[TBL] [Abstract][Full Text] [Related]
14. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Maniratanachote R; Shibata A; Kaneko S; Yamamori I; Wakasugi T; Sawazaki T; Katoh K; Tokudome S; Nakajima M; Yokoi T
Toxicology; 2005 Dec; 216(1):15-23. PubMed ID: 16115720
[TBL] [Abstract][Full Text] [Related]
15. DILI and drug development: a regulatory perspective.
Avigan MI
Semin Liver Dis; 2014 May; 34(2):215-26. PubMed ID: 24879985
[TBL] [Abstract][Full Text] [Related]
16. From the Food and Drug Administration.
Nightingale SL
JAMA; 1997 Dec; 278(21):1728. PubMed ID: 9388135
[No Abstract] [Full Text] [Related]
17. Troglitazone and liver injury: in search of answers.
Chojkier M
Hepatology; 2005 Feb; 41(2):237-46. PubMed ID: 15657914
[No Abstract] [Full Text] [Related]
18. Severe hepatotoxicity associated with bromfenac sodium.
Moses PL; Schroeder B; Alkhatib O; Ferrentino N; Suppan T; Lidofsky SD
Am J Gastroenterol; 1999 May; 94(5):1393-6. PubMed ID: 10235225
[TBL] [Abstract][Full Text] [Related]
19. Lessons from the glitazones: a story of drug development.
Gale EA
Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced liver injury in humans: the case of ximelagatran.
Keisu M; Andersson TB
Handb Exp Pharmacol; 2010; (196):407-18. PubMed ID: 20020269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
